Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

198
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
198
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.0K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

21
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
21
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

29
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
29
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

503
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
503

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a randomised placebo-controlled trial.

Health technology assessment (Winchester, England)·2026
Same author

The future of neonatology.

Archives of disease in childhood. Fetal and neonatal edition·2025
Same author

Improvements in Data Quality Can Boost Efficiency and Reduce Development Costs: A Pharmacometric CRO's Perspective.

The AAPS journal·2025
Same author

A rapid time-resolved host gene expression signature predicts responses to antibiotic treatment in neonatal bacterial sepsis.

Science translational medicine·2025
Same author

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists.

Clinical and translational science·2025
Same author

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model-Informed Drug Development Perspective.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: May 12, 2025

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

12.5K

Consideration for Assessing Data/Models/Tools Expiration Supporting Drug Development and Clinical Decision Making.

Jeffrey S Barrett1,2, Mark A Turner3,4

  • 1Aridhia Digital Research Environment, Glasgow, UK. Jeff.barrett@aridhia.com.

Therapeutic Innovation & Regulatory Science
|May 9, 2025
PubMed
Summary
This summary is machine-generated.

Data relevance for decision-making, especially in drug development, can decrease over time. Periodic reassessment of data value, considering factors like patient privacy and regulatory compliance, is crucial for maintaining its utility.

Keywords:
Clinical decision makingData expirationDrug developmentRegulatory science

More Related Videos

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.2K
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
13:10

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique

Published on: May 15, 2013

56.5K

Related Experiment Videos

Last Updated: May 12, 2025

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

12.5K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.2K
Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
13:10

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique

Published on: May 15, 2013

56.5K

Area of Science:

  • Biomedical Informatics
  • Data Science
  • Drug Development

Background:

  • Decision-making relies heavily on data, models, and tools.
  • Data is evaluated within a specific context of use (COU).
  • Implicit assumptions about data quality and relevance may not always hold true.

Purpose of the Study:

  • To explore factors impacting data information value over time.
  • To postulate occasions where data value diminishes, necessitating reassessment.
  • To consider data expiration and its impact on decision-making.

Main Methods:

  • Conceptual analysis of data value over time.
  • Examination of drug development as a case study.
  • Identification of factors influencing data relevance and information value.

Main Results:

  • Data relevance and information value are not static and can degrade over time.
  • Drug development presents scenarios where data value diminishes.
  • Periodic review and condition reassessment are necessary for data utility.

Conclusions:

  • Data expiration and time-dependent status changes should be considered for decision-making.
  • Patient privacy, consent, and regulatory compliance are critical factors for ongoing data use.
  • Understanding data information value dynamics is essential for both drug development and clinical decision-making.